The Clinical ink team collaborated with partners in academia and the pharmaceutical industry in WATCH-PD, a research study to validate remote, mobile assessments for use in capturing digital endpoints in PD.
Collecting rich mobile and sensor data, our machine learning-enabled analysis model distinguished healthy volunteers from patients with early-stage PD, providing preliminary support for the use of Clinical ink technology solutions in generating digital biomarkers associated with PD status. Ultimately, such evidence should lead to regulatory acceptance and widespread adoption of the assessments in Parkinson’s clinical trials and clinical development.
Download our case study to learn more.
